Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02662452 | First-in-Human Single and Multiple Dose of GLPG2222 | PHASE1 | COMPLETED | 40 | — | — | Jan 1, 2016 | May 1, 2016 | Jul 29, 2016 | 1 | Belgium |
To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of adverse events
To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal laboratory parameters
To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal vital signs
To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal electrocardiogram
To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal physical examination
To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal pulmonary function as measured by spirometry
| Arm | Type | Description |
|---|---|---|
| GLPG2222 single dose | EXPERIMENTAL | Single dose of GLPG2222 oral suspension |
| Placebo single dose | PLACEBO_COMPARATOR | Single dose of placebo oral suspension |
| GLPG2222 multiple doses | EXPERIMENTAL | Multiple doses of GLPG2222 oral suspension |
| Placebo multiple doses | PLACEBO_COMPARATOR | Multiple doses of placebo oral suspension |
| Name | Type | Description |
|---|---|---|
| GLPG2222 single dose | DRUG | single ascending doses, oral suspension |
| Placebo single dose | DRUG | single doses, oral suspension, matching placebo |
| GLPG2222 multiple doses | DRUG | multiple ascending doses, daily for 14 days, oral suspension |
| Placebo multiple doses | DRUG | multiple doses, daily for 14 days, oral suspension, matching placebo |
Inclusion Criteria: * Males between 18-50 years of age * Subjects must have a body mass index between 18-30 kg/m² * Subjects must be judged to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram and laboratory profile * Subject...